Equities
Health CareMedical Equipment and Services
  • Price (USD)46.91
  • Today's Change-0.44 / -0.93%
  • Shares traded529.11k
  • 1 Year change-1.98%
  • Beta1.7677
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Enovis Corp had net income fall 150.23% from a loss of 13.29m to a larger loss of 33.26m despite a 9.22% increase in revenues from 1.56bn to 1.71bn. An increase in the selling, general and administrative costs as a percentage of sales from 35.92% to 36.58% was a component in the falling net income despite rising revenues.
Gross margin56.96%
Net profit margin-6.03%
Operating margin-6.20%
Return on assets-2.43%
Return on equity-3.59%
Return on investment-2.66%
More ▼

Cash flow in USDView more

In 2023, Enovis Corp increased its cash reserves by 84.53%, or 20.54m. The company earned 134.99m from its operations for a Cash Flow Margin of 7.91%. In addition the company generated 127.80m cash from financing while 242.47m was spent on investing.
Cash flow per share2.66
Price/Cash flow per share18.09
Book value per share59.61
Tangible book value per share-8.23
More ▼

Balance sheet in USDView more

Enovis Corp has a Debt to Total Capital ratio of 28.76%, a higher figure than the previous year's 11.48%.
Current ratio2.27
Quick ratio1.12
Total debt/total equity0.404
Total debt/total capital0.2876
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -39.18%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-6.88
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.